Monopar Therapeutics (MNPR) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics is the larger company by market cap ($563.7 million vs $508.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | MPLT |
|---|---|---|
| Share price | $83.98 | $9.15 |
| Market cap | $563.69M | $508.52M |
| 1-day change | +0.24% | -2.24% |
| YTD return | +28.61% | -47.91% |
| 1-year return | -14.80% | — |
| 5-year return | +242.08% | — |
| EPS (TTM) | $-2.20 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $40.43 |
| 52-week low | $50.07 | $8.92 |
| Distance from 52-week high | -32.72% | -77.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +54.70% | +190.05% |
| Average volume | 215.52K | 858.68K |
| Shares outstanding | 6.71M | 52.85M |
| Employees | 22 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
MNPR vs MPLT FAQ
Which is bigger, Monopar Therapeutics or MapLight Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $563.69M compared with $508.52M for MapLight Therapeutics (MPLT).
Are Monopar Therapeutics and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.